Top

Published in:

01-10-2014 | Editorial

Regadenoson for myocardial perfusion imaging: Is it safe?

Author: Fadi G. Hage, MD, FASH, FACC

Published in: Journal of Nuclear Cardiology | Issue 5/2014

Excerpt

Regadenoson is currently the most widely used pharmacologic stress agent for myocardial perfusion imaging (MPI) with millions of doses administered annually in the US. In November 2013, the US Food and Drug Administration (FDA) issued a Drug Safety Communication warning health care professionals of the rare but serious risk of heart attack and death with use of either regadenoson or adenosine.1 In this issue of the Journal, Rosenblatt et al report on 2 cases of asystole following regadenoson administration for MPI in stable outpatients.2 These reports raise legitimate concerns with regard to safety of regadenoson considering its widespread use and the dictum of “do no harm.” …

http://www.fda.gov/drugs/drugsafety/ucm375654.htm. Accessed April 30, 2014.

Rosenblatt J, Mooney D, Dunn T, Cohen M. Asystole following regadenoson infusion in stable outpatients. J Nucl Cardiol 2014;In same issue of this editorial.

Hsi DH, Marreddy R, Moshiyakhov M, Luft U. Regadenoson induced acute ST-segment elevation myocardial infarction and multivessel coronary thrombosis. J Nucl Cardiol 2013;20:481-4.PubMedCrossRef

Shah S, Parra D, Rosenstein RS. Acute myocardial infarction during regadenoson myocardial perfusion imaging. Pharmacotherapy 2013;33:e90-5.PubMedCrossRef

Bagley SJ, Lilly SM, Litwack AJ. Coronary vasospasm during a regadenoson stress test. Cardiol J 2012;19:92-4.PubMedCrossRef

Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58.PubMedCrossRef

Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. J Am Coll Cardiol Cardiol Image 2008;1:307-16.CrossRef

Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-20.PubMedCrossRef

Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S. A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 2012;19:319-29.PubMedCrossRefPubMedCentral

10.

Doukky R, Morales Demori R, Jain S, Kiriakos R, Mwansa V, Calvin JE. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. “The ASSUAGE trial”. J Nucl Cardiol 2012;19:448-57.PubMedCrossRef

11.

Partington SL, Lanka V, Hainer J, Blankstein R, Skali H, Forman DE, et al. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test. J Nucl Cardiol 2012;19:970-8.PubMedCrossRefPubMedCentral

12.

Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681-92.PubMedCrossRefPubMedCentral

13.

Parker MW, Morales DC, Slim HB, Ahlberg AW, Katten DM, Cyr G, et al. A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial. J Nucl Cardiol 2013;20:185-96.PubMedCrossRef

14.

Ross MI, Wu E, Wilkins JT, Gupta D, Shen S, Aulwes D, et al. Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial. J Nucl Cardiol 2013;20:197-204.PubMedCrossRef

15.

Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A, Morales Demori R. The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation. J Nucl Cardiol 2013;20:205-13.PubMedCrossRef

16.

AlJaroudi WA, Alraies MC, Cerquiera MD, Jaber WA. Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response. Eur J Nucl Med Mol Imaging 2013;40:341-8.PubMedCrossRef

17.

Brinkert M, Reyes E, Walker S, Latus K, Maenhout A, Mizumoto R, et al. Regadenoson in Europe: First-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy. Eur J Nucl Med Mol Imaging 2014;41:511-21.PubMedCrossRefPubMedCentral

18.

Zoghbi GJ, Iskandrian AE. Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol 2012;19:126-41.PubMedCrossRef

19.

Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzein E, et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 2001;298:209-18.PubMed

20.

Shryock JC, Snowdy S, Baraldi PG, Cacciari B, Spalluto G, Monopoli A, et al. A2A-adenosine receptor reserve for coronary vasodilation. Circulation 1998;98:711-8.PubMedCrossRef

21.

Pandit A, Unzek Freiman S. Complete heart block associated with regadenoson: A real side effect. J Nucl Cardiol 2012;19:1236-9.PubMedCrossRef

22.

Grady EC, Barron JT, Wagner RH. Development of asystole requiring cardiac resuscitation after the administration of regadenoson in a patient with pulmonary fibrosis receiving n-acetylcysteine. J Nucl Cardiol 2011;18:521-5.PubMedCrossRef

23.

Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702.PubMedCrossRef

24.

Minic Z, O’Leary DS, Scislo TJ. Nucleus tractus solitarii A(2a) adenosine receptors inhibit cardiopulmonary chemoreflex control of sympathetic outputs. Auton Neurosci 2014;180:32-42.PubMedCrossRef

25.

Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J 2009;157:771-6.PubMedCrossRef

26.

Hage FG, Dean P, Iqbal F, Heo J, Iskandrian AE. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2011;18:1086-94.PubMedCrossRef

27.

Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006;45:1201-12.PubMedCrossRef

28.

Zhao G, Serpllion S, Shryock J, Messina E, Xu X, Ochoa M, et al. Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs. J Cardiovasc Pharmacol 2008;52:467-73.PubMedCrossRef

29.

Yesil M, Arikan E, Postaci N, Bayata S, Yilmaz R. Locations of coronary artery lesions in patients with severe conduction disturbance. Int Heart J 2008;49:525-31.PubMedCrossRef

30.

Abuin G, Nieponice A, Barcelo A, Rojas-Granados A, Leu PH, Arteaga-Martinez M. Anatomical reasons for the discrepancies in atrioventricular block after inferior myocardial infarction with and without right ventricular involvement. Tex Heart Inst J 2009;36:8-11.PubMedPubMedCentral

31.

Saadjian AY, Gerolami V, Giorgi R, Mercier L, Berge-Lefranc JL, Paganelli F, et al. Head-up tilt induced syncope and adenosine A2A receptor gene polymorphism. Eur Heart J 2009;30:1510-5.PubMedCrossRef

32.

Hurle A, Sanchez-Quintana D, Ho SY, Bernabeu E, Murillo M, Climent V. Capillary supply to the sinus node in subjects with long-term atrial fibrillation. Ann Thorac Surg 2010;89:38-43.PubMedCrossRef

33.

Andreassi MG, Laghi Pasini F, Picano E, Capecchi PL, Pompella G, Foffa I, et al. Adenosine A2(A) receptor gene polymorphism (1976C>T) affects coronary flow reserve response during vasodilator stress testing in patients with non ischemic-dilated cardiomyopathy. Pharmacogenet Genomics 2011;21:469-75.PubMedCrossRef

34.

2013 Nuclear Cardiology Trend Survey. J Nucl Cardiol 2014;21:Supplement 1.

35.

https://www.fbo.gov/index?s=opportunity&mode=form&id=a54939566ff0f502b8da95ab23e34d2b&tab=core&tabmode=list&=. Accessed 05/02/2014.

36.

Stuart RJ Jr, Ellestad MH. National survey of exercise stress testing facilities. Chest 1980;77:94-7.PubMedCrossRef

37.

Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994;23:384-9.PubMedCrossRef

38.

Lette J, Tatum JL, Fraser S, Miller DD, Waters DD, Heller G, et al. Safety of dipyridamole testing in 73,806 patients: The Multicenter Dipyridamole Safety Study. J Nucl Cardiol 1995;2:3-17.PubMedCrossRef

39.

Geleijnse ML, Fioretti PM, Roelandt JR. Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol 1997;30:595-606.PubMedCrossRef

40.

Sokol DK. “First do no harm” revisited. BMJ 2013;347:f6426.PubMedCrossRef

Title: Regadenoson for myocardial perfusion imaging: Is it safe?
Author: Fadi G. Hage, MD, FASH, FACC
Publication date: 01-10-2014
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 5/2014
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-014-9922-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Regadenoson for myocardial perfusion imaging: Is it safe?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2014

Quantification of I-123-meta-iodobenzylguanidine Heart-to-Mediastinum Ratios: Not So Simple After All

Are absolute myocardial blood flow PET measurements ready for clinical use?

Buccal caffeine for the routine reversal of Persantine

Prognostic value of normal stress myocardial perfusion imaging in diabetic patients: A meta-analysis

Multimodality cardiac imaging of a patient with syncope

Preclinical characterization of a novel radiolabeled analog of practolol for the molecular imaging of myocardial β-adrenoceptor density

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page